Is Egrifta (Tesamorelin) Legal in Arizona? A Women's Health Guide

Import from '@/components/mdx'

The Short Answer: Tesamorelin Is Legal in Arizona

Egrifta is legal in Arizona. Full stop. It is an FDA-approved drug with two approved branded formulations, Egrifta and Egrifta SV, both manufactured by Theratechnologies. Any Arizona-licensed prescriber can write for it. Any Arizona-licensed pharmacy can dispense it.

No Arizona state statute, Arizona State Board of Pharmacy rule, or Arizona Medical Board regulation specifically bans or restricts tesamorelin beyond the standard controlled-substance and prescription-drug framework that applies to all prescription medications. Arizona follows federal law under 21 U.S.C. § 353 for dispensing prescription drugs, which requires a valid prescriber-patient relationship and a licensed pharmacy.

The confusion about legality usually comes from two sources: the broader "peptide" category (many peptides are research chemicals with no approved status), and the availability of compounded tesamorelin from compounding pharmacies. Both deserve a careful look, especially if you are a woman evaluating this drug for your specific health situation.

FDA Approval Status: What It Means for You

The Approved Indication

The FDA approved tesamorelin in November 2010 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The approval was based on two Phase 3 randomized controlled trials (LIPO-010 and LIPO-011), in which tesamorelin 2 mg subcutaneously once daily reduced visceral adipose tissue (VAT) by a mean of 17.8% versus 2.1% with placebo at 26 weeks.

The approval covers both sexes. Women were included in both key trials, though they represented a smaller proportion of participants because HIV-associated lipodystrophy has a higher prevalence in men with HIV. This is one of the evidence gaps you deserve to know about (see the women-specific section below).

Egrifta vs. Egrifta SV

Two formulations exist. The original Egrifta requires reconstitution in sterile water and delivers 2 mg per dose. Egrifta SV (single-vial) uses a citrate-free formulation and was approved in 2019 with the same dose and indication. Both are available through specialty pharmacies. Your Arizona prescriber can write for either.

Federal vs. Arizona State Legal Framework

Federal Layer

At the federal level, tesamorelin is a prescription drug under the Food, Drug, and Cosmetic Act, not a controlled substance under the DEA Controlled Substances Act. This means it does not carry Schedule II-V restrictions. A prescriber in Arizona does not need a DEA number specifically for tesamorelin (though most prescribers maintain one). The prescription must comply with 21 CFR Part 201 labeling requirements.

Arizona State Layer

The Arizona State Board of Pharmacy (ASBP) licenses pharmacies under A.R.S. Title 32, Chapter 18. Tesamorelin does not appear on any Arizona restricted-drug schedule. The Arizona Medical Board and Arizona Board of Osteopathic Examiners govern prescribers; neither has issued a tesamorelin-specific restriction.

Prescribers in Arizona can legally prescribe tesamorelin off-label, as they can any FDA-approved drug, as long as the prescribing meets the standard of care. Off-label prescribing is legal under both federal law and Arizona medical practice statutes.

The Compounding Question

Compounded tesamorelin is where the legal picture gets more layered. FDA-approved drugs can be compounded by 503A (traditional) and 503B (outsourcing facility) pharmacies under specific conditions set by the Drug Quality and Security Act of 2013. Because branded Egrifta is commercially available, compounders must demonstrate a "clinical difference" for a patient to justify compounding (e.g., a documented allergy to an excipient). The FDA has not placed tesamorelin on its list of bulk drugs prohibited for compounding, but it has also not placed it on the positive "Category 1" list of bulk substances approved for 503A compounding.

In practice, licensed compounding pharmacies in Arizona and nationally do currently compound tesamorelin for prescribers who request it. This is not the same as a gray-area research chemical. The drug has known pharmacology, a characterized safety profile, and FDA-approved labeling. You should still confirm that any compounding pharmacy your provider uses holds current PCAB accreditation or operates as an FDA-registered 503B outsourcing facility.

The WomanRx Regulatory Tier Framework for Tesamorelin:

| Tier | Status | Example | |---|---|---| | 1 (fully clear) | FDA-approved brand, licensed pharmacy | Egrifta / Egrifta SV | | 2 (permissible with documentation) | Compounded from licensed 503A/503B for documented clinical need | PCAB-accredited AZ compounder | | 3 (not recommended) | Unregulated online "research" sources | Any gray-market supplier |

Always use Tier 1 or documented Tier 2. Tier 3 has no place in women's clinical care.

How to Get Egrifta in Arizona: A Step-by-Step Path

Getting tesamorelin in Arizona requires three things: a licensed prescriber, a documented clinical indication, and a licensed pharmacy.

Step 1: Find a Qualified Prescriber

Any Arizona-licensed MD, DO, NP (with prescriptive authority), or PA can prescribe tesamorelin. For the FDA-approved indication, you need a confirmed diagnosis of HIV-associated lipodystrophy. For off-label use, you need a prescriber willing to document clinical rationale, which is standard medical practice.

Infectious disease physicians, endocrinologists, and women's-health specialists with metabolic medicine training are the most common prescribers. Telehealth prescribers licensed in Arizona can also prescribe it, provided they conduct an appropriate clinical evaluation and can document a prescriber-patient relationship consistent with Arizona telemedicine law (A.R.S. § 36-3601).

Step 2: Establish Clinical Need

Your prescriber will review your fasting lipid panel, fasting glucose or HbA1c, IGF-1 level, and body composition data. A DEXA scan or CT/MRI quantifying visceral adipose tissue is standard for establishing the baseline. These tests are not optional formalities; the clinical evidence base for tesamorelin is built around objective VAT measurement, and your prescriber needs this data to monitor response and justify ongoing treatment.

Step 3: Fill the Prescription

Egrifta and Egrifta SV are available through specialty pharmacies including Walgreens Specialty Pharmacy, CVS Specialty, and others. Call ahead to confirm Arizona availability. Insurance coverage for the on-label indication is possible but requires prior authorization. For off-label use, out-of-pocket costs apply; branded Egrifta SV runs approximately $3,000 to $6,000 per month without insurance, though manufacturer patient-assistance programs exist through Theratechnologies.

Tesamorelin and Women's Physiology: What the Evidence Actually Shows

This is where the clinical picture gets specific to you as a woman, and where honesty about the evidence matters.

The Evidence Gap

The key tesamorelin trials enrolled predominantly men. LIPO-010 enrolled 412 participants, and women with HIV-associated lipodystrophy were represented, but subgroup data by sex were not prominently published. This means the 17.8% VAT reduction figure is not reliably sex-stratified. Extrapolation to women, particularly women without HIV, carries a meaningful evidence gap. Any prescriber who claims strong female-specific efficacy data for tesamorelin is overstating what exists.

Sex-Specific Pharmacokinetics

Growth hormone secretion differs by sex. Women naturally have higher GH pulse amplitude and more frequent GH secretory episodes than men of the same age, a difference that narrows significantly after menopause. This means that a woman's IGF-1 response to a GHRF analogue like tesamorelin may differ from a man's, though direct PK/PD comparisons in women across reproductive stages are not available in the published literature. Your prescriber should monitor IGF-1 levels and adjust expectations accordingly.

Perimenopause and Postmenopause

This is where women have the most clinical interest in tesamorelin. Menopause drives a well-documented shift toward central (visceral) fat deposition, even in women who maintain stable body weight. Data from the Study of Women's Health Across the Nation (SWAN) showed that the menopausal transition independently increased VAT, separate from aging effects. Visceral fat increases cardiovascular risk, insulin resistance, and metabolic syndrome risk in postmenopausal women.

Tesamorelin's mechanism, stimulating endogenous GH release and thereby raising IGF-1, addresses one contributor to postmenopausal VAT accumulation (declining GH pulsatility). Small investigator-initiated studies have explored this. A pilot study published in the Journal of Clinical Endocrinology and Metabolism found that tesamorelin reduced VAT in non-HIV adults, but the sample included few women, and the effect size in women specifically was not reported separately.

Menopausal hormone therapy (MHT) with estrogen has its own favorable effect on body composition. If you are already on MHT, your prescriber needs to account for the interaction: estrogen affects IGF-1 bioavailability and GH sensitivity, and combining MHT with a GHRF analogue requires careful IGF-1 monitoring.

PCOS

Women with polycystic ovary syndrome have altered GH secretion, often with lower GH pulse amplitude despite normal or elevated IGF-1 in some phenotypes. Whether tesamorelin would be beneficial or potentially counterproductive in a woman with PCOS and hyperinsulinemia is genuinely unknown. No published trial has examined this population. Until data exists, tesamorelin in PCOS should be considered investigational and should not be prescribed outside a clinical protocol.

Reproductive-Age Women Without HIV

Tesamorelin has no FDA-approved indication in reproductive-age women without HIV. Off-label use for "metabolic optimization" or body composition in this group lacks any controlled trial data. The theoretical concern is IGF-1 elevation and its effects on breast tissue, ovarian function, and potentially hormone-sensitive conditions. These risks are not established, but the absence of safety data is a reason for caution, not a reason to assume safety.

Pregnancy, Lactation, and Contraception: Required Reading

Pregnancy

Tesamorelin is contraindicated in pregnancy. This is a hard stop, not a nuanced clinical tradeoff.

The FDA label for Egrifta states that tesamorelin should be discontinued if pregnancy occurs. Animal reproduction studies showed adverse embryo-fetal effects at doses relevant to human exposure. The FDA label classifies tesamorelin based on a risk that cannot be excluded in humans, and no adequate and well-controlled studies in pregnant women exist.

IGF-1 elevation during early pregnancy is a biologically meaningful concern. IGF-1 plays a role in placental development and fetal growth, and exogenous manipulation of the GH-IGF-1 axis during organogenesis carries theoretical risk. The absence of human safety data does not mean the drug is safe in pregnancy; it means the risk is unknown and the label appropriately defaults to contraindication.

If you are trying to conceive, you should not start tesamorelin. If you are on tesamorelin and become pregnant, stop the drug immediately and notify your prescriber.

Contraception Requirement

Any woman of reproductive potential prescribed tesamorelin should use reliable contraception. This is not a legal requirement written into the FDA label the way it is for isotretinoin (which has REMS), but it is the clinically responsible standard. Your prescriber should document this discussion. WomanRx recommends discussing contraceptive options before starting tesamorelin if you are premenopausal.

Lactation

No human data exist on tesamorelin transfer into breast milk. The molecular weight of tesamorelin (5135 daltons) suggests that transfer into milk is possible, though oral bioavailability in an infant would likely be low because peptides are digested. "Likely low" is not the same as zero risk. The FDA label states that breastfeeding is not recommended during tesamorelin treatment. Given the absence of safety data, WomanRx and the clinicians on our editorial board agree with this recommendation.

Who This Is Right For (and Who Should Wait)

Women Who May Be Appropriate Candidates

• Women with confirmed HIV-associated lipodystrophy and excess VAT, which is the on-label indication
• Postmenopausal women with significant central adiposity and documented low GH pulsatility, evaluated by an endocrinologist in a carefully monitored off-label protocol
• Women who have discussed cardiovascular risk reduction goals with their provider and for whom lifestyle interventions and MHT have been insufficient or are not appropriate

Women Who Should Not Use Tesamorelin

• Pregnant women or women actively trying to conceive
• Breastfeeding women
• Women with active malignancy or a history of hormone-sensitive cancer (tesamorelin elevates IGF-1, and IGF-1 is associated with breast cancer risk)
• Women with diabetic retinopathy (tesamorelin can worsen glucose homeostasis and is associated with new-onset diabetes in approximately 4.5% of treated patients)
• Women with pituitary disease or tumors (tesamorelin acts at the hypothalamic-pituitary axis)
• Reproductive-age women without HIV seeking off-label metabolic optimization without a formal clinical protocol

Life-Stage Summary

| Life Stage | Tesamorelin Use | |---|---| | Reproductive years, no HIV | Not established; off-label data absent | | Trying to conceive | Contraindicated | | Pregnant | Contraindicated | | Postpartum / breastfeeding | Not recommended | | Perimenopause | Possible off-label with close monitoring; IGF-1 titration needed | | Postmenopause | Most investigated off-label group; discuss with endocrinologist | | Women with HIV-associated lipodystrophy | On-label; supported by Phase 3 data |

Monitoring If You Are Prescribed Tesamorelin

Your prescriber should check IGF-1 at baseline and at 3 to 6 months on treatment. The target is an IGF-1 within the normal range for your age; IGF-1 above the upper limit of normal should prompt dose reduction or discontinuation. Fasting glucose and HbA1c should be monitored at least every 6 months given the glucose-elevating effects of GH pathway activation. The FDA label specifically notes glucose intolerance as a known adverse effect.

VAT response should be assessed at 26 weeks using the same modality used at baseline (DEXA or imaging). If VAT has not decreased meaningfully by 6 months, continuation is not justified.

Fluid retention, arthralgias, and injection-site reactions are the most commonly reported adverse effects. In the Phase 3 trials, edema occurred in approximately 6% of tesamorelin-treated patients versus 2% of placebo patients. Women may be more symptomatic with fluid retention given baseline hormonal influences on sodium handling, though sex-stratified adverse event data from the key trials is not published.

A Note from WomanRx on the "Peptide Optimization" Trend

The peptide market has expanded rapidly. Many providers, particularly in the direct-to-consumer telehealth space, market peptides including tesamorelin as "metabolic optimization" tools with minimal regulatory framing. Some of what is sold online as "tesamorelin" comes from unregulated international suppliers with no assurance of purity, sterility, or actual peptide identity.

As WomanRx editorial board member Dr. Maya Okafor, MD notes: "My concern with women seeking tesamorelin outside a proper clinical evaluation is not the drug itself, which is well-characterized. It is the absence of baseline IGF-1 measurement and the lack of a plan to monitor glucose. Women in perimenopause are already at rising metabolic risk. Adding a drug that can worsen insulin sensitivity without monitoring is a clinical mistake, not a wellness upgrade."

Tesamorelin obtained through Tier 3 sources (unregulated online markets) is not the same product as FDA-approved Egrifta. You cannot verify purity, dose accuracy, or sterility. This is a meaningful safety risk, not a bureaucratic one.

Frequently Asked Questions